July 07, 2025 a 12:39 pm
ELV: Analysts Ratings - Elevance Health Inc.
Elevance Health Inc. shows a consistent interest from analysts, maintaining a strong position in the health benefits industry. With a notable market presence, the company is observed to receive predominantly favorable ratings, indicating a stable investor confidence. Such ratings reflect the company’s growth potential supported by its diversified product portfolio and strategic initiatives.
Historical Stock Grades
| Rating | Count | Score |
|---|---|---|
| Strong Buy | 5 | |
| Buy | 13 | |
| Hold | 4 | |
| Sell | 0 | |
| Strong Sell | 0 |
Sentiment Development
- The distribution of analyst ratings for Elevance Health has shown stability over recent months, with the majority in the Buy and Strong Buy categories.
- No significant increase in Sell or Strong Sell ratings indicates sustained confidence among analysts.
- While there was a notable increase in Buy ratings earlier, recent months have stabilized.
- Strong Buy ratings saw a slight decline compared to a year ago, but have recently plateaued.
- A consistent number of Hold ratings, suggesting some caution amidst general optimism.
Percentage Trends
Analyzing percentage trends highlights shifts in analyst sentiment towards the stock over time. Here's a summary of rating distribution over the recent months:
- Strong Buys have slightly decreased, dropping from 20% to 15% over the year.
- Buys have maintained a strong presence, consistently holding between 60-65% of total recommendations.
- Hold ratings have remained stable, showing a minor increase of 5% towards the mid-year.
- No Sell or Strong Sell recommendations have been noted, indicating sustained positive outlooks.
Latest Analyst Recommendations
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-06-09 | Buy | Buy | Truist Securities |
| 2025-06-04 | Outperform | Outperform | RBC Capital |
| 2025-06-02 | Overweight | Overweight | Barclays |
| 2025-04-25 | Buy | Buy | Argus Research |
| 2025-04-23 | Overweight | Overweight | Barclays |
Analyst Recommendations with Change of Opinion
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-04-15 | Neutral | Outperform | Baird |
| 2025-03-17 | Buy | Hold | Argus Research |
| 2024-10-18 | Hold | Buy | Argus Research |
| 2024-07-18 | Neutral | Buy | B of A Securities |
| 2023-07-12 | Peer Perform | Outperform | Wolfe Research |
Interpretation
The overall market sentiment for Elevance Health shows robust analyst confidence, underpinned by consistent Buy ratings. The lack of Sell or Strong Sell ratings suggests no overarching concerns in the market. However, some caution is noted, as evidenced by stable Hold recommendations. The consistency of Buy recommendations adds credibility to the company's performance outlook, with favorable growth expectations. Recent downgrades to Neutral indicate some variability in confidence, possibly suggesting a need for closer monitoring of market conditions.
Conclusion
Elevance Health Inc. presents a solid investment opportunity with favorable analyst sentiment. Despite minor downgrades, the predominant Buy and Outperform ratings highlight a strong market position. The absence of Sell ratings reinforces investor confidence. Analysts remain optimistic about the company's potential, ensuring its place in a competitive industry. While some caution is advised, overall sentiment remains positive, making Elevance Health a viable option for long-term investment. Investors are encouraged to monitor any market changes closely to manage risks effectively.